NeurAxis, Inc.: NeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue Growth
NeurAxis (NYSE American: NRXS) reported Q2 2026 revenue of $1.9M, up 116% year over year, citing PENFS Category I CPT code coverage effective Jan. 1, 2026. Gross margin rose to 85.9%. Cash was $8.3M at June 30, 2026. The company also cited VA FSS contract and FDA clearance for functional dyspepsia abdominal pain.
How this was made
The 30-second read
Why it matters
This quarter links revenue and gross margin expansion to the effective Jan. 1, 2026 Category I CPT code for PENFS, while adding new access catalysts: VA FSS contract and first-ever FDA clearance for functional dyspepsia-related abdominal pain in patients 8+.
Market read
Traders can reassess NRXS’s reimbursement-driven growth trajectory and near-term adoption expectations ahead of the scheduled earnings call, given multiple access milestones alongside reported financial expansion.
What to watch
Operating loss and net loss increased year over year, and cash burn remains meaningful; investors may discount the quarter if gross margin expansion does not persist as discounted assistance programs change.
Background
NeurAxis commercializes IB-Stim (PENFS) for pediatric and adult functional GI conditions, with adoption tied to payer coverage and coding.
Ticker impact
NeurAxis reported 2Q26 revenue up 116% to $1.9M, citing Category I CPT coverage for PENFS effective Jan. 1, 2026.
Near-term upside bias as investors price in accelerating reimbursement-driven adoption and new market access milestones.
The release combines hard financials (revenue, gross margin, cash) with discrete access catalysts (CPT effectiveness, FDA clearance, VA contract). However, it does not provide forward guidance or consensus context, limiting conviction on magnitude and sustainability.
Market effects
Reimbursement and coding changes appear to be a key demand lever for neuromodulation devices, reinforcing the importance of payer policy execution in medtech.
No specific regional demand shift is quantified, but management highlights higher utilization where insurance barriers are lower.
Primarily US-focused (CPT, FDA clearance, VA FSS), with limited direct global read-through.
Counterpoint
Despite strong growth, the company’s absolute revenue base remains small ($1.9M quarterly), so results may be volatile and sensitive to payer coverage timing and mix.
Key entities
- public_companyNeurAxis, Inc.
NYSE American-listed neuromodulation medical technology company reporting 2Q26 results and new payer, FDA, and federal contracting milestones.
- product_therapyPercutaneous Electric Nerve Field Stimulation (PENFS)
NeurAxis proprietary neuromodulation therapy whose reimbursement coverage and clinical clearances drive adoption.
- regulatory_reimbursementCategory I CPT code assignment for PENFS
Payer coverage milestone effective Jan. 1, 2026, cited as the driver of unit deliveries and revenue growth.
- government_contractVeterans Affairs Federal Supply Schedule (FSS) contract
Federal contractor designation enabling a commercial pathway into the VA health system.
- regulatory_approvalFDA clearance for functional dyspepsia (FD) abdominal pain with nausea, age 8+
New indication clearance expanding the addressable market for IB-Stim.
